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INTRODUCTION 
 
 The presence of meconium in the amniotic fluid is relatively 
common. It remains a concern for the obstetrician because meconium 
passage is associated with increased perinatal morbidity and mortality 
and its association with meconium aspiration syndrome and its sequelae. 
Infants born through meconium stained amniotic fluid are more likely to 
be depressed at birth and require resuscitation and neonatal intensive 
care.  
 The significance of presence of meconium in labour is 
controversial. Meconium aspiration can occur in utero, during the process 
of birth or after birth. The persistence of meconium aspiration syndrome 
despite suctioning at birth may be related to intrauterine aspiration.  
 In the past meconium stained amniotic fluid has been associated 
with fetal distress. Passage of meconium has been a marker of antepartum 
or intrapartum asphyxia.      
 But now invitro passage of meconium is considered a physiological 
consequence of normal gastrointestinal tract maturation, and this event 
alone might not indicate fetal distress.  
 The overall frequency of meconium stained amniotic fluid varies 
between 10% to 15%. If this meconium stained fluid is aspirated by the 
fetus before or during birth, meconium can obstruct the airways, cause 
inflammation, interfere with surfactant function and cause respiratory 
difficulties resulting in meconium aspiration syndrome (MAS). The 
syndrome is characterized by the development of respiratory distress in 
an infant born through meconium stained amniotic fluid whose symptoms 
cannot otherwise be explained.   
 Meconium aspiration syndrome occurs in 5-10% of infants born 
through meconium stained amniotic fluid and in 10-40% of  newborns 
with meconium below vocal cords. It is a life threatening emergency in 
term babies. Despite intensive management it is associated with increased 
mortality of about 10% -40%. It is a leading cause of respiratory distress 
in the new born. 
 Infants with severe meconium aspiration syndrome  develop 
pulmonary hypertension and cardiopulmonary failure requiring 
extracorporeal membrane oxygen (EMCO). Those who survive may 
demonstrate residual neurological deficits. Therefore there is great 
interest in developing strategies to prevent meconium aspiration 
syndrome. Initial attempts were aimed at neonatal management, later a 
perinatal approach to the problem was recommended including suctioning 
the oropharynx at birth in infants with meconium stained amniotic fluid.   
Since the presence of thick meconium was associated with poor outcome 
in infant, amnioinfusion was suggested. Amnioinfusion, the instillation of 
normal saline into the uterine cavity during labour has been proposed as a 
method 
a) To reduce the meconium concentration by diluting the meconium 
on the trachea and thus decreasing the potential of developing 
obstruction of airways and development of meconium aspiration 
syndrome.  
b) It reduces cord compression in cases of oligohydramnios for which 
thick meconium is a marker and therefore fetal gasping and 
prevents inutero aspiration.   
 
 
 
 
 
 
 
 
 
 
AIM OF THE STUDY 
 
1. To evaluate intrapartum transcervical amnioinfusion as a 
therapeutic intervention in thick meconium stained amniotic fluid. 
a. To reduce the incidence of caesarean section. 
b. To prevent meconium aspiration syndrome.  
c. To reduce perinatal morbidity and mortality in cases of 
meconium stained amniotic fluid.   
 
 
 
 
 
 
 
 
 
 
 
 
 REVIEW OF LITERATURE 
                             
 During the 1950s and 1960s it was thought that meconium stained 
amniotic fluid was marker of fetal compromise and efforts were made to 
deliver the foetus either before or as soon as meconium appeared.  
 Amnioscopy was introduced, for post dated pregnancies and 
Saldana and associates showed no benefit from amnioscopy and delivery.  
 Because meconium passage is more common with advanced 
gestation age, many studies (Cole and associates) have investigated  the 
effect of inducing labour at an earlier gestation between 39-40wk. But no 
effect on perinatal mortality or respiratory disease was seen. 
 Later it was widely believed that meconium aspiration developed 
by inhalation of meconium at delivery when the infant took, its first 
breath. To prevent this aggressive policies of oropharyngeal suction, 
endotracheal intubation, cricoid pressure and splitting of thorax were 
proposed which had little effect on aspiration.      
 Gabbe and Co-workers (1976) showed in monkeys that removal of 
amniotic fluid produced variable decelerations and that replenishment of 
fluid with saline relieved the deceleration.  
 Miyazaki and Taylor (1983) used amnioinfusion for variable or 
prolonged decelerations due to cord entrapment. Fetal heart rate pattern in 
half of the women studied improved.  
 Miyazaki and Nevarez (1985) found that women treated with 
amnioinfusion for cord compression pattern, less often required caesarean 
delivery for fetal distress.  
 Intrapartum amnioinfusion was initially proposed by Wenstrom 
and Parsons as a way of diluting the meconium to decrease the incidence 
of meconium aspiration syndrome. They showed a significant reduction 
in meconium below cords.  
 Sadavosky (1989) found that amnioinfusion effectively decreases 
the frequency of thick meconium, frequency of neonatal acidemia, and 
frequency of meconium below vocal cords and meconium aspiration 
syndrome. 
 Wenstrom and Parson 1989 reported that amnioinfusion decreases 
meconium below vocal cords, low one minute apgar scores and lower 
operative delivery rate.  
 Marci et al (1992) reported significant reduction in fetal distress, 
significant reduction in caesarean section for fetal distress and decreased 
incidence of meconium aspiration and meconium aspiration syndrome.  
 Eriksen et al (1994) reported decreased incidence of meconium 
below vocal cords and meconium aspiration syndrome.  
 Cialone et al (1994) reported decreased incidence of meconium 
below cords, decreased fetal acidemia and meconium aspiration 
syndrome. 
 Demeenus et al (1997) reported significant decrease in caesarean 
sections.  
 Hofmeyr et al (CRAMP-1) (in South Africa). The Collaborative 
Randomised Amnioinfusion for Meconium Project study 1998 did not 
show a significant  reduction in caesarean section or meconium aspiration 
syndrome. However when they pooled their dated with Zimbabwe 
(CRAMP 2) study they demonstrated a significant effect of 
aminoinfusion in reducing caesarean section and meconium aspiration 
syndrome.      
 Puertas et al (1999) reported reduced caesarean section for fetal 
distress and decreased incidence of meconium below  vocal cords.  
 Pierce et al (2000) in a meta analysis of prospective trials reported 
that amnioinfusion improves the neonatal outcome and lowers the rate of 
caesarean delivery and does not increase the rate of postpartum 
endometritis.   
 Hofmeyr (2002) in Cochrane Data base review, a systematic  
review of randomized trails, demonstrated that aminoinfusion reduced the 
rates of meconium aspiration syndrome and caesarean delivery.  
 Rathore et al (2002) reported decreased caesarean section rate, 
decreased incidence of meconium at vocal cords and improved neonatal 
outcomes.  
 Shah (2004) reported amnioinfusion as the ideal method of 
preventing fetal distress due to meconium stained amniotic fluid and 
reported decreased incidence of meconium aspiration syndrome and 
perinatal mortality and morbidity.  
 Sood et al (2004) reported that amnionfusion decreased the 
incidence of caesarean section, meconium aspiration and hospital stay.  
 There are conflicting reports on the results of prophylactic 
amnionfusion. Two studies question the routine use of amnioinfusion.  
 Studies by Spong et al and Usha et al do not indicate any definite 
improvement with amnioinfusion for meconium stained amniotic fluid.    
 Spong (1994) and colleagues concluded that there was no 
difference in outcome between the amnioinfusion group and standard 
group and suggested that benefit of amnioinfusion is the result of 
alleviation of variable heart rate deceleration.   
 Similarly Usha et (1995) reported no difference in meconium 
aspiration syndrome with amnio infusion.  
 Hofmeyr Y et al (2007) in a systematic review of randomized 
controlled trial reported that in clinical settings with standard peripartum 
care amnioinfusion does not reduce meconium aspiration syndrome, but 
in setting with limited peripartum surveillance amnioinfusion reduced the 
risk of meconium aspiration syndrome. 
 However in a recent study Das et al (2007) observed significant 
decrease of caesarean deliveries, meconium aspiration syndrome and 
perinatal deaths. 
 
AMNIO INFUSION – GUIDELINES 
 
Definition  
 It is the artificial instillation of a sterile solution of normal saline or 
ringer lactate into the uterine cavity usually performed transcervically 
during intrapartum period. It is a beneficial intervention in meconium 
stained amniotic fluid. This procedure is effective and easy to perform 
and safe.  
 INDICATIONS  
Therapeutic  
A. Antepartum  
1. Treatment or prevention of complications caused by 
oligohydramnios in preterm pregnancies both diagnostic and 
therapeutic to prevent pulmonary hypoplasia.  
2. In pregnancies complicated by preterm PROM, serial 
amnioinfusion results in significant prolongation of pregnancy and 
better neonatal outcome.        
B. Intrapartum  
1. Intrapartum transcervical amnioinfusion for prevention of 
meconium aspiration syndrome caused by meconium stained, 
amniotic fluid.  
2. Reduction of variable fetal heart rate deceleration during labour 
caused by umbilical cord compression.    
Diagnostic  
In oligohydramnios aminoinfusion can be used for improving 
ultrasound imaging. 
 Contraindications  
1. Active maternal genital herpes infection 
2. Diminished FHR variability or reactivity  
3. Fetal scalp PH <7.2 
4. Late decelerations in fetal heart rate 
5. Placenta praevia  
6. Placental abruption 
7. Chorioamnionitis  
8. Fetal  malpresentation  
Relative contraindications  
1. Fetal anomalies  
2. Impending delivery  
3. Multiple gestation  
4.  Prior caesarean delivery  
5. Uterine anomalies  
Technique  
1. Sterile Ringer lactate solution or Normal saline  
The fluid may be at room temperature for term gestations.  
2. Double lumen intrauterine pressure catheter  
3. Fetal monitor  
4. Intravenous tubing 
5. Continuous close monitoring using a fetal scalp electrode   
Infusion protocols 
 Many different amnioinfusion protocols have been reported. 
1. 500-800ml bolus of normal saline at room temperature over 30 
minutes followed by continuous infusion of approximately 
3ml/minute for thick meconium stained amniotic fluid.  
2. Initial bolus of 250ml normal saline at 10 to 20ml per hour infused 
over 20-30 minutes. An additional 250ml beyond the volume at 
which decelerations resolve is administered. Amnioinfusion may 
be repeated if gross fluid leakage occurs or variable FHR 
deceleration appear. The amnioinfusion is unsuccessful if infusion 
of 1000ml does not result in termination of deceleration.  
 
Route of administration 
a. Transcervival: Infusion of normal saline via a catheter in 
uterine cervix.  
b. Transabdominal performed via amniocentesis spinal needle.  
 This procedure is typically performed during labor through an intra 
uterine catheter introduced transcervially after rupture of the membranes. 
Alternatively fluid can be infused through a needle trans abdominally.  
 The transcervical route is preferred because it does not require 
ultrasound guidance and easily allows for repeated fluid instillation.  
  The fetal heart rate and resting tone are assessed continuously 
during the intervention.  
Complications 
1. Uterine over distension or hyperactivity  
2. Amniotic fluid embolism  
3. Placental abruption  
4. Cord prolapse 
5. Chorioamnionitis  
6. Uterine rupture  
7. Maternal cardiopulmonary compromise  
Role of amnioinusion  
The passage of thick meconium inutero puts the neonate at risk for 
meconium aspiration. The risk of meconium aspiration is high in patients 
with thick meconium particularly when it is associated with episodes of 
fetal hypoxemia. Thin meconium is not associated with increased 
perinatal mortality rate or an increased increase of meconium aspiration 
syndrome. Therefore any mechanism by which thick meconium can be 
converted to thin meconium has a positive effect on neotal outcome and 
decrease the incidence of meconium aspiration. 
 In meconium stained amniotic fluid aminoinfusion 
a. Is used to reduce the risk of meconium aspiration syndrome 
by diluting the meconium.  
b. Artificially by increasing amniotic fluid volume corrects 
oligohydramnios resulting from rupture of membranes, there 
by reducing vagal stimuli due to cord compression and thus 
reduce the number and severity of variable deceleration. 
These probably decrease further meconium passage as well 
as remove a stimulus for deep breathing and gasping and 
prevents meconium aspiration.    
c. Amnioinfusion may allow spontaneous vaginal delivery and 
avoid the necessity of operative intervention.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SIGNIFICANCE OF MECONIUM IN AMNIOTIC FLUID 
 
Meconium  
      Meconium is a viscous green fluid and consists of gastrointestinal 
secretions, bile, mucous, desquamated fetal cells, langue, vernix, blood 
and amniotic fluid. The dark greenish black appearance is caused by 
pigments especially biliverdin.  
Meconium passage  
d. Inutero passage of meconium is uncommon due to relative 
lack of strong peristalsis, good anal sphincteric tone and the 
viscous meconium cap at the lower end of gastrointestinal 
tract.  
e. Three theories have been suggested to explain fetal passage 
of meconium which may explain the tenuous connection 
between the detection of meconium and infant mortality.  
i. Inutero passage of meconium may be normal 
gastrointestinal tract maturation and neural control i.e, 
from normal bowel peristalsis.  
ii. The pathological explanation proposes that the foetus 
pass meconium in response to hypoxia and that 
meconium therefore signals fetal compromise. 
Hypoxia stimulates arginine vasopressin (AVP) 
release from the fetal pitutary gland. AVP stimulates 
the smooth muscle of colon to contract resulting in 
intra amniotic defaecation.  
iii. Third meconium passage could follow vagal 
stimulation from common but transient umbilical cord 
entrapment and resultant increased peristalsis. Thus 
fetal release of meconium also could represent 
physiological process.      
1. The effect of maturity and gestation on passage of meconium  
 Meconium is found in fetal gut from 10 wks gestation. But 
meconium passage is uncommon before 37 wks and most common in 
post term pregnancy. After 42 wks it is 30-50%, 30% at 40 wks and 50% 
at 42 wks. It reflects fetal gastrointestinal maturity and increased gut 
motility as gestational age increases.    
 Meconium passage in the preterm foetus can occur if it becomes 
infected with organisms that cause fetal enteritis (eg.listeria, ureoplasma 
etc). 
  
Cumulative meconium passage by gestational age 
 
Study  
 
Meconium passage  
Eden and associates (1987) 
 39 wks  
 40 wks  
 42 wks  
 > 42 wks  
 
14 
19 
26 
29 
Usher and colleagues (1988) 
 39-40 wks 
 41 wks  
 42 weeks or greater  
 
15 
27 
32 
Steer & Co-workers (1989) 
 < 36 wks  
 36-39 wks  
 40-41 wks  
 42 weeks or greater  
 
3 
13 
19 
23 
 
 
 
 
 
2. Hormonal control of passage of meconium  
 The intestinal hormone motilin has been implicated in the passage 
of meconium inutero. It causes contraction of smooth muscle in gut wall. 
The levels of motilin increase with gestation and stress on the foetus 
could cause release of motilin and thus passage of meconium.  
3. Infection and passage of meconium  
 Meconium stained amniotic fluid is associated with increased 
peripartum infection rates especially thick meconium. It is unclear 
whether the presence of meconium encourages infection or whether 
infection promotes the passage of meconium.  
4. Obstetric cholestasis  
  The risk of meconium passage increases in association with 
cholestasis of pregnancy.  
Risk Factors  
 Earlier it was suggested that fetal hypoxia causes meconium 
passage inutero, but it now stated that hypoxia and acidosis per se do not 
lead to passage of meconium.  
 The predictive value of meconium as an indicator of asphyxia is 
better when it occur in high risk patients and when it is dark thick and 
tenaceus.  
 Passage of meconium into normal amniotic fluid results in its 
aspiration before labour and in healthy well oxygenated foetus this 
diluted meconium is cleared from lungs by normal physiological 
mechanism. When this meconium is not cleared, the meconium aspiration 
syndrome results. It can occur after normal labour but more likely in  
• Post term pregnancy  
• IUGR baby  
• Diminished amniotic fluid volume with cord compression  
• Uteroplacental insufficiency  
   The compromised fetus cannot clear the thick undiluted meconium. 
Meconium aspiration  
  The passage of meconium is not a risk to the foetus, but aspiration 
of meconium into the fetal lung is associated with clinical disease ranging 
from mild respiratory distress to severe respiratory compromise and 
occurs in 1/3rd cases. Meconium aspiration is defined as the presence of 
meconium below vocal cords and occurs in 10-40% of live births with 
meconium stained amniotic fluid.  
 Meconium aspiration may occur  
• Inutero 
• During the process of birth or  
• After birth  
     It seems likely that meconium aspiration is largely an intrauterine 
event. Two types of breathing movement cause inhalation of amniotic 
fluid inutero gasping and deep breathing. Gasping usually occurs during 
hypoxemia. But in majority of infants the exact timing is not clear.  
   Postnatal inhalation can occur late in the second stage or 
immediately after delivery if the infant gasps or makes breathing 
movement while the oropharynx, hyopharynx or trachea contains 
meconium stained amniotic fluid.  
 
MECONIUM ASPIRATION SYNDROME 
 
 Meconium aspiration syndrome represents a wide spectrum of 
disease from transient respiratory distress with little therapy required to 
severe respiratory compromise requiring prolonged mechanical 
ventilation and high levels of oxygen administration.   
It is the commonest cause of respiratory distress in term and 
postterm infants and its severity linked to coexisting fetal asphyxia and 
ultimately leads to respiratory failure. meconium aspiration syndrome 
occur in 10-40% of infants both through meconium stained amniotic 
fluid.  
Occurs in more than 30% of pregnancies that continue past 42 wks.  
Of infant delivered through MSAS 5-33% develop respiratory 
symptoms and radiographic changes of meconium aspiration syndrome. 
Up to 30% of these infants require mechanical ventilation.  
Approximately 1/3rd develop persistent pulmonary hypertension 
which contributes to the mortality associated with the syndrome.  
Pathophysiology of meconium aspiration syndrome 
The pathophysiology of meconium aspiration syndrome is 
extremely complex due to interplay of number of mechanisms.  
 
The respiratory disorders occurs of  
a. Obstructive nature of the aspirated viscus meconium 
which produces airway obstruction with obstructive 
emphysema due to ball valve effect.  
b. Pronouned inflammatory response occur within hours 
of aspiration and protein leaks in the airways occur.  
c. Cytokines and eicosanoids are often present and may 
contribute to pulmonary vasoconstriction and tissue 
damage and persistent pulmonary hypertension.  
d. Meconium causes dysfunction of endogenous 
surfactant.  
e. Meconium affects neutrophil function, and is 
associated with increased risk of infection.  
Clinical features  
 After resuscitation, initial apnoea is followed by progressive 
respiratory distress with intercostal retraction and grunting. The AP 
diameter of the chest increases and appears emphysematous. The course 
is progressive during initial 48-72 hrs and may be complicated by 
persistent pulmonary hypertension leading to intractable hypoxemia and 
acidosis.  
 X-ray findings range from classic description of diffuse patchy, 
infiltrates or lobar consolidation to a relatively clear virtually normal 
appearance of lung fields.   
 
Prognosis  
 The outcome of meconium aspiration syndrome is guarded. The 
case fatality late varies between 5% to 35%. There is a high risk of 
cerebral palsy, seizures and mental retardation among survivors 
depending upon the severity and duration of perinatal asphyxia. These 
infants are vulnerable to develop recurrent respiratory infection, reactive 
airway disease and chronic pulmonary insufficiency during childhood.  
 
Management of infants born through meconium stained 
amniotic fluid  
Intrapartum management  
 If meconium is detected continuous electronic fetal heart rate 
monitoring during labour is recommended. If fetal heart rate pattern is 
abnormal immediate delivery by caesarean section is considered.  
 When meconium of any consistency is present intrapartum, the 
obstetrician should clear the infants nose and oropharynx before delivery 
of shoulders with a bulb syringe or a Dee Lee suction catheter.   
 Recently it has been suggested that routine orophoryngeal suction 
in the absence of evidence of hypoxia should not be performed as it does 
not reduce the incidence of meconium aspiration syndrome.  
 
 
 
 
 
 
 
 
 
 
 
Postpartum management  
 At delivery a pediatrician should be present (experienced in 
neonatal resuscitation).  
 
 
 
 
 
 
 
 
 
 
 20-30% infants will be depressed at perineum. In these cases the 
baby is handed over to the pediatrician. The trachea is intubated under 
direct laryngoscopy before initial respiratory efforts have been initiated 
and intratracheal suctioning is done to remove the meconium from the 
airway.  
 The infant’s general condition should not be ignored during the 
attempts to clear the trachea. This procedure should be accomplished 
Infant is vigorous  
[Heart rate >100min  
Spontaneous Respiration Good Tone] 
Infant is non vigorous 
depressed or has 
respiratory distress 
Trachea is intubated 
under direct laryngscope  
Tracheal suction  Routine care is given no 
tracheal suctioning  
All infants born through meconium stained 
amniotic fluid  
Suction before delivery of shoulders   
Assess 10-15 seconds after delivery    
rapidly and ventilation with oxygen should be initiated before significant 
bradycardia occurs. 
Management of Meconium Aspiration Syndrome 
• Infants depressed at birth and have had meconium suctioned 
from trachea are at risk from meconium aspiration 
pneumonia and closely observed for respiratory distress.  
• Oxygen saturation is monitored.   
• X-ray chest is taken. 
1. Routine care  
 Baby should be nursed in  
• Thermoneutral environment and  
• Oxygen is given by head box  
• Mechanical ventilation when respiratory failure is impending 
• Fluid and nutritional support  
• Broad spectrum antibiotics in infants with respiratory 
distress and abnormal radiological findings   
• Corticosteroids are contraindicated  
• Indwelling arterial catheter is required for blood sampling 
and arterial blood gas analysis 
 
2. Non conventional management includes   
• High frequency ventilation  
• Exogenous surfactant  
• Inhaled nitric oxide  
• Liquid ventilation 
• Extracorporeal membrane oxygen [ECMO] 
3. Acute complications  
a. Air leak pneumothorax or pneumomediastinum occurs in 10-20% 
of patients with meconium aspiration syndrome more frequently 
with mechanical ventilation.  
b. Pulmonary hypertension associated with meconium aspiration 
syndrome occurs in 35% cases and inhaled nitric oxide is given.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
 
This study was conducted in Govt. Rajaji Hospital, Madurai from 
Sept 2006 to Sept 2007.  
 200 patients with pregnancy at or beyond 37 weeks with a single 
live fetus in cephalic presentation and moderate to thick meconium 
stained amniotic fluid was included in the study.  
 It was a prospective comparative evaluation of two groups of 100 
women one group receiving amnioinfusion for meconium stained 
amniotic fluid and one receiving standard care (control). 
 Group A - Consisted of those who received amnioinfusion  
 Group B - Those who did not received amnioinfusion 
 (Control) 
 All women had moderate to thick meconium stained amniotic fluid 
seen after either spontaneous or artificial rupture of membranes.  
Inclusion criteria  
1. Singleton pregnancy  
2. Vertex presentation  
3. Gestational age of  37 wks or more  
4. Normal fetal heart rate  
5. Moderate and thick meconium  
6. Cervical dilatation of 3-8cm  
7. Women in active labour  
8. No major medical or obstetric complications.  
Exclusion criteria  
1. Major fetal anomaly  
2. Chorioamnionitis  
3. Placenta praevia  
4. Vaginal bleeding  
5. HIV infection  
6. Polyhydramnios 
7. Previous uterine incision  
8. Multiple gestation  
9. Fetal distress 
Procedure  
 After a detailed history taking including complications during the 
present pregnancy general physical examination and obstetric 
examination was made.  
Gestational age was confirmed by menstrual history, fundal 
examination and ultrasound.  
Routine haematological and urine examination was done.    
 All women had moderate to thick meconium stained amniotic fluid 
seen either after spontaneous or artificial rupture of membranes.  
 Further cervical dilatation, presentation, prolapse of cord, character 
of the meconium stained amniotic fluid and fetal heart rate variability was 
noted.  
 Thin meconium was defined as watery. Moderately meconium 
stained amniotic fluid as opaque without particles. Thick meconium as 
“pea soup” particles.  
 In the study group after explaining the procedure to the patient and 
getting her consent, under all aseptic precautions the amnioinfusion 
catheter (Ryles tube No.16) was inserted transvaginally and passed above 
the baby’s head with one end inside the uterine cavity and the other end 
outside connected outside to an intravenous tube. 500 ml of normal saline 
at room temperature was infused over 30-45 minutes until the meconium 
was washed out and the returning amniotic fluid was clear. In most 
patients 1 litre was transfused over 45 minutes.  
- Intravenous broad spectrum antibiotics was given for all the 
patients. 
- The control group did not receive any intrapartum 
amnioinfusion.  
 
- All women were monitored by fetal heart sound auscultation 
every 15 minutes. Criteria for fetal heart rate variation was 
both tachycardia and bradycardia.  
 
- Uterine activity was assessed every half an hour by 
palpation.  
 
- Augmentation for inadequate uterine contraction was done 
with syntocinon drip when no fetal bradycardia was 
recorded.  
 
- Outlet forceps or emergency caesarean section was done in 
those cases where there was a further deterioration of FHR, 
persistent bradycardia and non progress of labour.   
 
- A paediatrician was present at the time of delivery. 
 
- All neonates were managed by standard protocol of 
immediate oropharyngeal suction at delivery of the head by 
the obstetrician.  
 
- The paediatrician undertook subsequent recusitative 
procedures.   
 
- During fetal oropharyngeal suction, the presence of 
meconium below the vocal cords on laryngoscopic 
examination was documented.  
 
- If the infant was vigorous, no endotracheal intubation or 
suctioning was done.  
 
- The mode of delivery, duration between detection of 
meconium stained amniotic fluid, amnioinfusion and 
delivery of the foetus was noted.  
 
- Neonatal details considered were mode of delivery, apgar 
score of baby at 1 minute and 5 minutes, birth weight, 
presence of meconium below the vocal cords on 
laryngoscopic examination and meconium aspiration 
syndrome.  
- Evidence of IUGR, post maturity and congenital anomalies 
were looked.  
- Admission to nursery and complications including mortality 
were noted.  
- The parameters studied included operative intervention rates, 
meconium below vocal cords, meconium aspiration 
syndrome and post partum complication in the mother in the 
first 48 hrs.  
- Baby and mother were carefully followed in the postnatal 
ward for any morbidity and mortality.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OBSERVATION 
 200 patients attending Govt. Rajaji Hospital were included in this 
study.  Group A (100 patients) : study group with amnio infusion given. 
 Group B (100 patients) control group – No amnio infusion 
Table 1  
Age Distribution 
 
Study Group (A) Control Group (B) Age in years No. % No. % 
18-20 2 2 7 7 
20-24 56 56 49 49 
25-29 30 30 37 37 
30-34 10 10 5 5 
35 & above 2 2 2 2 
Total 100 100 100 100 
Mean 
S.D. 
24.53 years 
3.51 years 
24.26 yrs 
3.88 yrs 
‘p’ 0.5958 Not significant 
 
 88% in the study group and 93% in the control group were below 
30 group of age. Only minority were above the age of 30 years. 12% in 
study group and 7% in control group. Age distribution was comparable 
among the two groups and majority (90%) of the patients were between 
18-30 years age group. 
 
 
Table 2  
Obstetric Index 
Study Group 
A 
Control Group 
B Obstetric 
Index No. % No. % 
Primi 51 51 54 54 
Multi 49 49 46 46 
Total 100 100 100 100 
‘p’ 0.777 (Not significant) 
 
 The two groups were similar in the distribution of gravidity. In 
Group A: 51% of the patients were primigravidas and 49% were 
multigravidas. In Group B: 54% of the patients were primigravidas and 
46% were multigravidas. 
Table 3  
Gestational Age 
 
Study Group 
A 
Control Group 
B  
Gestational Age in 
weeks 
No. % No. % 
37-39 weeks 52 52 56 56 
40-41 weeks 44 44 41 41 
41 weeks & above 4 4 3 3 
Total 100 100 100 100 
Mean  
S.D. 
39.26 
2.34 
39.15 
2.42 
‘p’ 0.8226 (Not significant) 
 
Gestational age 
 In group A 52% of patients came under the gestational age of 37-
39 weeks, 44% were in the gestational age of 40-41 weeks, and 4% were 
above 41 weeks. 
 In group B 56% were in gestational age of 37-39, 41% were in 
gestational age of 40-41 weeks and 3% were above 41 weeks. 
 
Table 4  
Cervical Dilatation 
 
Study Group 
A 
Control Group 
B 
Cervical 
Dilatation in cms 
No. % No. % 
3-5 cms 62 62 56 56 
6-8 cms 38 38 44 44 
Total 100 100 100 100 
Mean 
S.D. 
5.45 cms 
1.78 
5.6 cms 
1.92 
‘p’ 0.4534 (Not significant) 
 
Cervical dilatation 
 62% patient in group A and 56% patients in group B were having 
cervical dilation of 3-5 cm on inclusion. 
Table 5 
Degree of Meconium 
 
Study Group 
A 
Control Group 
B 
Degree of 
Meconium 
No. % No. % 
Moderate 49 49 53 53 
Thick 51 51 47 47 
Total 100 100 100 100 
‘p’ 0.6713 (Not significant) 
 
 49% patients in study group  and 53% patients in control group  
had moderate meconium stained amniotic fluid. Whereas 51% patients in 
study group and 47% patients in control group had thick meconium 
stained amniotic fluid. 
 
 
 
 
 
 
Table 6  
Oxytocin Augmentation 
 
Study Group 
A 
Control Group 
B 
Oxytocin 
Augmentation 
No. % No. % 
Yes 38 38 31 31 
No 62 62 69 69 
‘p’ 0.3721 (Not significant) 
 
 62% of the study group and 69% of the control group had normal 
spontaneous labour. 
 Where as 38% patients in study group and 31% patients in control 
group required oxytocin augmentation in labour the ‘p’ value is 0.3721 
which is not statistically significant. 
Table 7 
Amnio infusion to delivery interval in hours 
 
Amnio infusion 
to delivery 
interval in 
hours 
Primi Multi Total Cases 
1 hour and less 4 3 7 7 
1.1-2 hours 20 18 38 38 
2.1-3 hours 21 24 45 45 
3.1-5 hours 6 4 10 10 
Total 51 49 100 100 
Mean 
S.D. 
130.6 minutes 
50.6 minutes 
2 hrs 9 minutes 
50 minutes 
‘p’ 0.8279 (Not significant) 
 
 The mean interval between amnioinfusion to delivery was 130 
minutes in study group . It is a reflection of the time period the foetus has 
been surrounded by the environment containing meconium and there was 
enough time for amnioinfusion to have its effect .   
Table 8  
Fetal heart rate abnormalities in Labour 
 
Study Group 
A 
Control Group 
B 
FHR 
Abnormalities 
in labour No. % No. % 
Present 19 19 38 38 
Absent 81 81 62 62 
‘p’ 0.0048 
(Significant) 
 
 FHR abnormalities (tachycardia / Bradycardia) were less common 
in A group 19% compared to 38% in group B. Hence there were more 
cases of fetal distress in group B, the ‘P’ value is 0.0048 which is 
significant. Thus amnioinfusion significantly decreases FHR 
abnormalities  
Table 9 
Mode of Delivery 
 
Study Group 
A 
Control Group 
B Mode of 
Delivery Primi Multi Total % Primi Multi Total %
Labour 
Natural 
33 44 77 77 28 35 63 63
Outlet 6 3 9 9 9 6 15 15
LSCS 12 2 14 14 17 5 22 22
‘p’ 0.0449 (Significant) 
 
 Majority of the patients delivered by labour natural in both groups. 
77% in study group vs 63% in the control group. 
 Outlet forceps was applied for 9% in study group vs 15% in control 
group. Caesarean section was done for 14% in study group and 22% in 
control group. The p value is 0.0449 which is significant. There is 
decreased incidence of caesarean section in the amnioinfused group thus 
amnioinfusion decreases  incidence of caesarean  section.    
Table 10  
Intrapartum operative intervention 
 
Study Group 
A 
Control Group 
B Intervention 
Primi Multi Total % Primi Multi Total %
LSCS 12 2 14 14 17 5 22 22
Forceps 6 3 9 9 9 6 15 15
Total 18 5 23 23 26 11 37 37
‘p’ 0.0449 (Significant) 
 
 There is an increase in intrapartum intervention in control group. 
There is decreased number of caesarean section in study group compared 
to control group (14% vs 22%). There is also decrease number of outlet 
forceps in study groups compared to control group (9% vs 15%). Taking 
together the operative interventions in the study group and control group 
(23 patients in A group vs 37 patients in group B), there was decreased 
intervention in A group.  P value (0.0449) which is significant. Hence 
amnioinfusion reduces the operative interventions. 
 
 
 
Table 11 
Intervention for fetal distress  
Reason  A B 
 P M T % P M T % 
LSCS 9 2 11 11 16 4 20 20 
For 
fetal 
distress Forceps 5 2 7 7 6 5 11 11 
 Total  14 4 18 18 22 9 31 31 
p value = 0.0485  
LSCS 2 1 3 3 1 1 2 2 For 
other 
reason 
Forceps 
1 1 2 2 3 1 4 4 
 Total  3 2 5 5 4 2 6 6 
 
 There is increased intervention for fetal distress in group B 31% 
compared to 18% in group A. The p value is 0.0485 and is statistically 
significant. The incidence for LSCS for fetal distress in group B is high 
20% vs 11% in group A. The incidence of outlet forceps was also 11% in 
group B, compared to 7% in group A, Hence amnioinfusion decreases the 
operative intervention for fetal distress.   
Table 12 
Apgar Score 
Study Group          
(A) 
Control Group       
(B) Apgar Score 
No. % No. % 
1 Minute 
0-6 
7-10 
 
16 
84 
 
16 
84 
 
45 
55 
 
45 
55 
Mean 
S.D. 
6.74 
0.66 
6.21 
1.05 
‘p’ 0.0001 (Significant) 
5 Minutes 
0-6 
7-10 
 
7 
93 
 
7 
93 
 
18 
82 
 
18 
82 
Mean 
S.D. 
7.82 
0.52 
7.47 
0.96 
‘p’ 0.0032 (Significant) 
 
 In the study group, the low apgar score (0-6) at 1 minute was seen 
in 16% neonates in study group compared to 45% in control group. The P 
value is (0.001) which is significant. Similarly the low apgar score at 5 
minute was seen in 7% neonates in study group compared to 18% 
neonates in control group the p value is (0.0032) which is significant 
Thus amnioinfusion improves apgar score at 1 minutes and 5 minutes and 
improves neonatal out comes. 
 
 
 
 
 
Table 13 
Presence of Meconium below vocal cords 
Study Group 
A 
Control Group 
B Group 
No. % No. % 
Meconium below 
vocal cords 
Present 
Absent 
 
 
13 
87 
 
 
13 
87 
 
 
41 
59 
 
 
41 
59 
‘p’ 0.0001 
(Significant) 
MAS 
Among Present(13) 
Among Absent(87) 
 
3(13) 
1(87) 
 
23.1 
1.1 
 
19(41) 
4(59) 
 
46.3 
6.8 
‘p’ 0.0002 
 (Significant) 
 
 Meconium below vocal cords visualized by direct laryngoscopy 
was seen in 13% neonates in group A compared to 41% patients in group 
B the p value is 0.001 which is significant. 
 Meconium aspiration developed in 3 out of 12 neonates in group A 
(23%) compared to 19 out of 41neonates in group B (46.3%). The p value 
is 0.002 which is significant. Hence amnioinfusion decreases meconium 
below vocal cords and meconium aspiration syndrome. 
Table 14  
Birth Weight 
Study Group 
A 
Control Group 
B 
Birth Weight 
(in kg) 
No. % No. % 
Less than 2  - - - - 
2-2.5 14 14 21 21 
2.6-3 39 39 38 38 
>3 47 47 41 41 
Total 100 100 100 100 
Mean 
S.D. 
3 kg 
0.38 kg 
2.94 kg 
0.39 kg 
‘p’ 0.3605 (Not significant) 
 
 There was no significant difference in the birth weight between two 
group and the mean birth weight in group A was 3 kg and group was 
2.94kg. 
 
Table 15 
Admissions 
 
Study Group 
A 
Control Group 
B 
Reasons for 
admissions 
No. % No. % 
Observation 10 10 12 12 
MAS 3 3 15 15 
MAS WITH HIE 1 1 8 8 
Birth Asphyxia 2 2 6 6 
HIE - - 1 1 
Total Admission 16 16 42 42 
Not admitted 84 84 58 58 
‘p’  0.0002 
(Significant) 
 
 In the study group 16 neonates were admitted compared to 42 in 
the control group. In study group the incidence of meconium aspiration 
syndrome was 4 compared to 23 in the control group. In the study group 
most of the babies were admitted for observation only compared to the 
control group. The p value is 0.002 which is significant. Hence 
amnioinfusion results in decreased incidence of Neonatal intensive care 
unit admissions.  
Table 16 
Perinatal Mortality and Morbidity 
Study cases  
A 
Control cases
B  Parameter No. % No. % ‘p’ 
Perinatal Mortality 
1 1 8 8 
0.0175 
(Significant) 
Perinatal morbidity 
16 16 42 42 
0.0002 
(Significant) 
 
 Perinatal morality in study group is 1% where in control group it is 
8% p value of 0.0175 which is significant. In study group one neonate 
delivered by labour natural died after one week due to meconium 
aspiration with hypoxic ischemic encephalopathy (HIE-III).  
 Among control group B two neonates delivered by LSCS had 
meconium aspiration syndrome with HIE III and expired after 48 hrs. 
Among four neonates delivered by outlet forceps three neonates 
developed meconium aspiration with HIE III and one baby developed of 
meconium aspiration syndrome and died. Two neonates delivered by 
labour natural died of meconium aspiration syndrome. Hence 
amnioinfusion reduces perinatal mortality and morbidity.  
 
 
Table 17 
Maternal Outcome 
 
Study cases 
A 
Control cases 
B 
Maternal 
Outcome 
No. % No. % 
Uneventful 98 98 98 98 
Chrioamnionitis 1 1 2 2 
Uterine Hyper 
stimulation 
1 1 - - 
‘p’ 0.6894 
(Not significant) 
 
 
 There was no significant difference in maternal infection in both 
groups (1% of amnioinfused vs 2% of control). Hence amnioinfusion 
does not increase the infection rate. There was one case of uterine 
hyperstimulation in group A. 
 
 
 
 
Table 18  
Outcome of the Study 
Study Group 
A 
Control Group 
B 
P Value Out come 
No % No %  
1.Caesarean section  14 14 22 22 0.0449 
2. Foreps delivery 9 9 15 15 0.0449 
3. FHR abnormalities  19 19 38 38 0.0048 
4. Low Apgar <6   
 1 minutes 16 16 45 45 
0.0001 
 5 minutes 7 7 18 18 0.0032 
5. Meconium below 
the vocal cord  13 13 41 41 
0.001 
6.Meconium 
aspiration syndrome 4 4 23 23 
0.002 
7. Perinatal morbidity   16 16 42 42 0.0002 
8. Perinatal mortality  1 8 1 8 0.0175 
 
 Amnioinfusion results in significant reduction in caesarean section 
rate (14% vs 22%), decreased incidence of FHR abnormalities (19% vs 
38%) decreased incidence of low 1 min apgar score (16% vs 45%), 5 min 
apgar score (7% vs 18%), decreased incidence of FHR abnormalities 
(19% vs 38%) decreased incidence of meconium below vocal cords (13% 
vs 41%), decreased incidence of meconium aspiration syndrome (4% vs 
23%), decreased perinatal morbidity (16% vs 42%), decreased perinatal 
mortality (1% vs 8%).      
 
DISCUSSION 
 
 In this study a total of 200 women with moderate and thick 
meconium stained amniotic fluid were studied and divided into two 
groups. 100 in each group.  
Group A received amnioinfusion  
Group B did not receive amnioinfusion and standard care was given. 
 The two groups were comparable with respect to age, parity 
duration of pregnancy, gestation, cervical dilatation and labour 
characteristics.  
Mode of delivery  
1. Operative deliveries  
 The differences in the mode of delivery in both groups was 
significant p (0.0449). The incidence of caesarean section was 14% and 
outlet forceps 9% in group A compared to caesarean section 22% and 
outlet forceps 15% in group B. The total operative deliveries was 23% in 
group A compared 37% to group B. In the current study there is a drop in 
total operative deliveries in the study group (23% vs 37%).  
2. There is reduced caesarean section in the study group compared to 
control group B (14% vs 22%).  
3. There is reduced incidence of caesarean section for fetal distress in 
study group A compared to group B (11% vs 20%). 
 This coincides with the studies by Pierce et al who showed lower 
incidence of caesarean section in the amnioinfusion group (19.7% vs 
24.3%) and his instrumental delivery was 18%. Similar observations of 
lower incidence of operative deliveries have been made by several 
authors Das et al (18% of amnioinfused vs 30% of control) and Sahu et al 
also reported similar decrease in caesarean section. Wenstroms (6/36 of 
amnioinfused vs 15/44 of control), Ilagan NB et al (6/38 of amnioinfused 
vs 19/40 of control) reported significant decreased caesarean section rate 
and decreased assisted delivery (2/38 vs 7/40). Sood et al also reported 
(12% of amnioinfused vs 42% of control) decreased caesarean section 
rate. Demeenus et al reported decreased assisted delivery. (15.5% of 
amnioinfused vs 25.35% of control) and decreased caesarean delivery 
Kosha et al also reported significant decrease in section rate (4% of 
amnioinfused vs 28% of control). 
 
2. Fetal Heart Rate Abnormalities    
 The incidence of Fetal Heart Rate abnormalities was 19% in study 
group and 38% in control group. The caesarean section rates for fetal 
distress in study group was 11% and 20% in control group. Similarly 
outlet forceps for fetal distress in study group was 7% and 11% in control 
group. 
 Decreased caesarean section for fetal distress was reported by 
several authors. WuB et al (1991) reported significant reduction rates in 
caesarean section for fetal distress. Macri CJ & Schrimmer et al and (2/85 
of amnioinfused vs 17/85 of control) Peurtas et al similarly reported (1/40 
of amnioinfused vs 8/45 of control) reduction rates in caesarean section 
for fetal distress. 
 Demeenus et al reported a 6.75% caesarean section rate for fœtal 
distress in patients receiving amnioinfusion where as Sasikala et al 
reported 28% of women undergoing LSCS with fetal distress.    
 Erikson reported no significant difference in incidence of fetal 
distress or caesarean section for fetal distress. 
3. Meconium below vocal cords  
 Meconium below vocal cords was evident only in 13 patients 
receiving amnioinfusion compared to 41 patients in the non transfusion 
group, hence the presence of meconium below vocal cord was very much 
reduced by amnioinfusion (13% vs 41%) and is comparable to the studies 
of Sood etal (16% in amnioinfused group vs 48% in control group). 
Decreased incidence of meconium below vocal cards has been 
consistently reported by several authors Sadavosky (0% of amnioinfused 
vs 29% of control ) Wenstrom (2/36 of amnioinfused vs 16/44 of control) 
Macri & Shcrimmer (4/85 of amnioinfused vs 33/85 of control) Cialone 
(2/47 of amnioinfused vs 36/58 of control) Erikson (1/65 of amnioinfused 
vs 8/59 of control) Peurtas (4/40 of amnioinfused vs 14/45 of control) 
Pierce et al (4.9% of amnioinfused vs 22.9% of control) Shah (22% of 
amnioinfused vs 56% of control) Cramp 1 (4/162 of amnioinfused vs 
6/163 of control) Spong et al showed no difference in both amnioinfused 
and control groups.   
4. Meconium aspiration syndrome   
 The incidence of meconium aspiration syndrome was 4% in the 
study group compared to 23% in the non transfused group. Hence there is 
a decreased incidence of meconium aspiration syndrome in the 
amnioinfusion group. Similarly Das et al reported 4% in amnioinfused 
group and 18% in the control group. The decreased incidence of 
mecorium aspiration syndrome was reported by several authors.  
 Puertas (6.4% of amnioinfused vs24.9% of control) Wenstroms 
(0/36 of amnioinfused vs 3/44 of control) Macri & Shcrimmer (0/85 of 
amnioinfused vs 5/85 of control) Cialone (1/47 of amnioinfused vs 8/58 
of control) Erikson (0/65 of amnioinfused vs 2/59 of control), Mahomed 
(CRAMP):2 (3.1% of amnioinfused vs 12.8% of control), Pierce et al 
(2.5% of amnioinfused vs 8.5% of control), Sood (6% of amnioinfused vs 
20% of control).  
- In the study by Sadavosky, no infants developed meconium 
aspiration syndrome in the study and control group.  
- Kosha et al reported that neonatal parameters showed no 
significant difference in the amnioinfusion group. 
5. Apgar score  
 The low apgar score at 1 minute in the study group was 16% and in 
control it was 45%. Significantly fewer 1 minute up apgar scores <7, was 
reported by several author. This coincides with the study by Das et al 
12% of amnioinfused vs 47% of control) Wenstrom (11/36 of 
amnioinfused vs 23/44 of control) and Ilagan et al (6/38 of amnioinfused 
vs 13/40 of control) also reported low 1 minutes apgar scores.  
 The low apgar score in 5min was 7% in study group vs 18% in the 
control group. Mohamed et al in (CRAMP) reported (9/324 of 
amnioinfused vs 27/336 of control). Das et al (4% of amnioinfused vs 
23% of control), Shah (6% of amnioinfused vs 38% of control). 
 Rathore et al had only 1% babies in the study group with apgar <7 
at 5 min. Peurtas et al did not have any neonate at apgar <7 at 5 minutes 
in his study. 
 
6. Perinatal morbidity  
 In this study 42 neonates in group A and 16 neonates in group B 
was admitted in NICU (Neonatal intensive care unit). CRAMP study 
reported less NICU admission (41/321 of amnioinfused vs 76/332 of 
control) 
 Rathor et al reported fewer admission to NICU compared to 
controls Hofmeyr in Cochrane review also reported reduction in the 
intensive care unit admissions. 
 In this study nine neonates had hypoxic ischaemic encephalopathy  
in group B compared to one neonate in group A. Hence a decrease in HIE 
in amnioinfusion group. CRAMP study also reported decreased incidence 
of hypoxic encephalopathy (1/320 of amnioinfused vs 14/329 of control). 
Hofmeyr in Cochrane data base systematic view 2000 reported decreased 
incidence of  neonatal hypoxic ischaemic encephalopathy in the 
amnioinfused group. 
7. Perinatal mortality  
 In this study there is a trend towards reduced perinatal morality in 
amnioinfusion group 1% compared to control group 8% (1% vs 8%). Das 
et al reported similar perinatal mortality rate of 1% in study group and 
8.4% in control group. Shah et al (6% of amnioinfused vs 14% of control) 
Partha et al (1% of amnioinfused vs 3% of control). In cramp 2 study 
(1.2% of amnioinfused vs 3.6% of control). The Cochrane review showed 
a trend towards reduced perinatal mortality in the amnioinfusion group. 
8) Maternal outcome 
 There was no difference in maternal infection in both groups and 
hence amnioinfusion doesnot increase the rate of maternal infection.  
- Pierce et al reported that amnioinfusion does not increase the rate 
of post partum endometritis.  
- Mahomed (CRAMP) – reported that no complication related to 
amnioinfusion were observed. 
- Usta et al reported higher incidence of endometritis 
- Increased risk of chorio aminiontis – endometritis was reported by 
Spong et al. 
 
 
 
 
 
 
 
SUMMARY 
 
 200 patients admitted in the labour ward at Govt. Rajaji Hospital 
with moderate and thick meconium stained amniotic fluid, who met the 
criteria laid under inclusion categories were taken for this prospective 
comparative study. 
 They were allocated to two groups of 100 each. Group A 100 pt 
receiving trans cervical intrapartum amnioinfusion and Group B served as 
control  
In each group, the mode of delivery, development of fetal heart rate 
abnormalities , neonatal outcome and maternal outcome were recorded.  
 The results of the study are tabulated, analysed and summarised as 
follows. 
1. Majority (90%) of cases in both groups (88%) in study group and 
93% in control group were between 18-30 yrs. 
2. About half of the population in the study group were primigravida 
and the other half were multigravida Primi to multi ratio in group 
A being 51:49 Group B 54:46. 
3. Gestational age : About 52% patients in study group and 56% 
patients in control group were between 37-39 wks and rest were 
above 40 wks.  
4. More than half of the cases in this series had spontaneous labour 
(62% in study group and 69% in control) and the rest had 
augmented labour. (38% in study group & 31% in control group). 
5. 62% patient in study group and 56% patients in control group had a 
cervical dilatation of 3-5 cm on inclusion. 
6. The mean interval between amnioinfusion to delivery was 130 
minutes in the study, hence there was sufficient time for 
aminoinfusion to have its effect.   
7. About 49% patients in study group and 53% in control group had 
moderate meconium stained amniotic fluid where as 51% patients 
in study group and 47% patients in control group had thick 
meconuim stained amniotic fluid. 
8. Fetal heart rate abnormalities occurred in 19% in the study group 
and 38% cases in the control group. The p value is < 0.0048 which 
is significant. 
9. Mode of delivery. 
 a. In the ammioinfusion group (77%) had a vaginal delivery as 
 compared to only 63% of control group patients. 
 b. The incidence of caesarean section was 14% vs 22%  in the 
study and control group. Analyzing primigravida and multigravida 
separately caesarean section for fetal distress was required in 9% of 
primigravida in the study group and 16% in the control group and in 
2% and 4% of multigravida respectively. 
 The incidence of forceps deliveries was 9% versus 15% in the 
study and control group and for 7% in the study group and 11% in the 
control group the indication was fetal distress and the increased incidence 
in control group was due to fetal distress. 
7. Neonatal out come 
a. Low apgar score in one minute is 16% in study group vs 45% in 
control group, hence it is more common in group B. P value 0.001 
which is significant. 
b. Meconium below vocal cords was evident in 13% patients in 
receiving amnioinfusion compared to 41% in the control group of 
patients (p value is 0.001) which is significant. 
c. Meconium aspiration syndrome was seen to be markedly reduced 
by amnioinfusion. It occurred in 4% cases in amnioinfused  group 
and 23% of cases in the control group. The p value is 0.0002 which 
is significant. 
d. The mean birth weight in amnioinfusion group was 3kg and was 
comparable to control group 2.94 kg. 
e. The perinatal morbidity in amnioinfusion group was 16% 
compared to 42% in the control group the p value is 0.002 which is 
significant. 
f. The duration of nursery stay in both groups were similar. 
g. Perinatal mortality in the infusion group was 1% as compared to 
8% in the study group value is 0.0175 which is significant. 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
 
 Intra partum Amnioinfusion in moderate and thick meconium  
stained amniotic fluid resulted in 
1) Reduced incidence of FHR abnormalities (19%) compared to 38% 
who did not receive amnioinfusion. 
2) Reduction in caesarean section rate 14% of amnioinfused vs 22% 
of control. 
3) Significant reduction in intrapartum operative interventions for 
fetal distress 18% of amnioinfused vs 31% of control. 
4) Significant reduction in the presence of meconium below vocal 
cords 13% of amnioinfused vs 41% of control. 
5) Significant reduction in meconium aspiration syndrome 4% of 
amnioinfused vs 23% of control. 
6) Significant improvement in low 1 minute apgar and 5 minute apgar 
scores 16% of amnioinfused vs 45% of control and 7% of 
amnioinfused vs 18% of control. 
7) Significant reduction in perinatal morbidity 16% of amnioinfused 
vs 42% of control  
8) Significant reduction in perinatal mortality 1% of amnioinfused vs 
8% of control . 
Intrapartum transcervical ammioinfusion is a safe simple and inexpensive 
technique that  
a. Reduces fetal heart rate abnormalities. 
b. Reduces operative interventions for fetal distress  
c. Decreases the rate of caesarean delivery 
d. Improves neonatal outcomes by preventing meconium 
aspiration syndrome. 
e. Does not increase the rate of post partum endometritis 
f. Decreases perinatal mortality & morbidity.   
The presence of thick meconium is associated with increased 
perinatal morbidity and mortality. Meconium aspiration syndrome is a 
significant cause of perinatal mortality which can be reduced by 
amnioinfusion. In developing countries with limited intrapartum facilities 
amnioinfusion for thick meconium stained amniotic fluid improves 
perinatal outcome and decreases the caesarean section rates.   
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PROFORMA  
 
Case No :      Control No: 
 
Name :      Date of Admission: 
 
Age :       Unit : 
 
Address :      IP No: 
 
 
 
Urban : Rural   
 
Type of cases : Booked / unbooked 
 
LMP :  EDD: 
 
Menstrual H/o:  Regular / Irregular   
 
Period of gestation:  
 
Obstertic code : Gravida  Para   live  Abortion  
 
Inclusion criteria  
 
1. Singleton pregnancy 
2. Vertex presentation  
3. Gestational age of 37 wks or more 
4. Normal foetal heart rate  
5. Moderate and thick meconium 
6. Cervical dilatation of 3-8cm 
7. Women in active labour  
8. No major medical or obstetric complications   
 
Exclusion criteria  
 
1. Major foetal anomalies  
2. Chorioamnionitis  
3. Placenta praevia  
4. Vaginal bleeding  
5. HIV infection  
6. Polyhydramnios 
7. Previous uterine incision  
8. Multiple gestation  
9. Foetal distress  
 
History  
 
Relevant past H/o 
 
General Examination  
 
1. Height :   Weight :    Temperature: 
     
    Anaemia :   Pedal edema:  
     
    Pulse :   BP : 
 
    CVS :   RS : 
 
Obsteric Examination 
 
 P/A  - FHR variation  
 
 P/V → 1) Effacement  
   2) Dilatation  
   3) Station of vertex     
   4) Degree of meconium          Moderate:  Thick: 
         
Time of Amnioinfusion : 
 
Oxytocin Augmentation : yes / no 
 
Foetal distress in labour : Yes / No 
 
Mode of delivery  
 
 LN:  OUTLET :  LSCS: 
 
 
Time of delivery: 
 
Indication for LSCS / Instrumental delivery: 
 
Rupture of membranes to delivery interval: 
 
Baby Outcome: 
 
1. Weight : 
2. Sex : 
3. Live / Asphyxiated 
4. Apgar   1” 
        5” 
5. Meconium below cords:  
6. Any Anomalies 
7. Baby admitted : 
8. Reason for admission     1. Observation  
    2. Asphyxia  
    3. HIE (Hypoxic Ischemic Encephalopathy)
    4. MAS (Meconium Aspiration Syndrome)  
Maternal complication : 1. Yes  
    2. No 
 
     
 
 
 
 
 
 
MASTER CHART 
ABBREVIATIONS USED 
 
 AI   - Amnioinfusion  
 FHR   - Fetal Heart Rate 
 LN   - Labour Natural  
 LSCS   - Lower Segment Caesarean Section 
 FD   - Fetal Distress 
 V.C.   - Vocal cords  
 HIE   - Hypoxic ischemic Encephalopathy  
 MAS   - Meconium Aspiration Syndrome  
 B.A   - Birth Asphyxia  
 Ob   - Observation  
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Ventilation / perfusion mismatch  
 
PATHOPHYSIOLOGY OF MAS 
Aspiration of Meconium 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
            
 
 
 
 
 
 
 
Cytokines 
& 
Eicosanoids  
Inflammatory 
response  
 
Airway 
obstruction   
 
Dysfunction 
of surfactant 
 
Pulmonary 
vasoconstriction 
Protein leak in 
airway 
Obstructive 
emphysema   
Atelectasis, Hyaline 
membrane formation
Parenchymal 
lung injury  
Ball valve 
effect 
Chemical 
pneumonitis  
Hypoxemia / acidosis 
Pulmonary Hypertension 
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1 54438 24 Primi M Yes LN - Yes Female 2.15 6 8 No BA No Alive
2 54191 26 Multi M Yes LN - No Male 2.3 7 8 No No No Alive
3 55803 23 Multi T No LN - No Female 3.1 5 8 Yes Ob No Alive
4 56001 23 Primi T Yes LN - No Male 2.5 6 8 No BA No Alive
5 54518 23 Primi T Yes LN - No Male 3 7 8 No No No Alive
6 54529 29 Multi T No Outlet FD Yes Male 3.75 4 5 Yes MAS, HIE No Expired
7 56446 20 Primi M Yes LN - No Male 3.3 7 8 No No No Alive
8 55761 27 Multi T Yes Outlet FD Yes Female 2.8 6 8 No BA No Alive
9 56107 21 Primi M Yes LN - Yes Female 2.5 5 6 Yes MAS, HIE No Alive
10 51125 27 Primi T No LSCS FD Yes Female 2 7 8 No No No Alive
11 54665 29 Primi T No LSCS FD Yes Male 3 7 8 No No No Alive
12 58334 30 Multi M No LN - No Female 2.4 5 7 Yes MAS No Alive
13 59718 24 Primi M Yes LN - Yes Female 2.75 6 8 Yes Obs No Alive
14 58825 24 Multi T No LN - No Male 2.5 7 8 No No No Alive
15 59940 37 Multi T No LN - No Male 3.05 7 8 No No No Alive
16 51124 28 Multi T No LN - No Female 3.4 6 8 Yes MAS No Alive
17 60119 23 Primi T No Outlet FD Yes Female 3 5 7 Yes Obs No Alive
18 54995 28 Multi M No LN - No Female 3.1 7 8 No No No Alive
19 60827 23 Multi M Yes Outlet FD Yes Female 3.5 7 8 No No No Alive
20 62073 20 Primi M Yes LN - Yes Male 3.3 6 8 Yes No No Alive
21 62074 30 Multi T No LSCS FD Yes Male 3.2 7 8 No No No Alive
22 62049 19 Primi T Yes LSCS FD Yes Female 3.5 4.5 6 Yes MAS No Alive
MASTER CHART - GROUP B
23 62863 21 Primi M Yes LN - No Female 3 7 8 No No No Alive
24 63137 25 Primi M Yes LSCS FD Yes Male 3.3 7 8 Yes No No Alive
25 64494 24 Multi T Yes LN - No Female 3 7 8 No No No Alive
26 72284 26 Primi T No LSCS FD Yes Male 3.4 6 8 Yes MAS No Alive
27 66072 25 Multi T No Outlet No Female 3 5 6 Yes BA No Alive
28 63442 28 Multi T No LN - Yes Male 2.7 4 6 Yes Obs No Alive
29 63374 20 Primi M No LN - No Female 3.3 7 8 No No No Alive
30 63427 21 Primi M Yes Outlet FD Yes Male 3.8 7 8 Yes No No Alive
31 71996 23 Multi M No LN - No Male 2.6 7 8 No No No Alive
32 63604 20 Multi T No LSCS CPD No Female 2.6 7 8 No No No Alive
33 67297 26 Primi T Yes Outlet - No Male 3.25 5 7 Yes Obs No Alive
34 63541 20 Primi M No LN - No Female 2.1 7 8 No No No Alive
35 67372 22 Primi T No LSCS FD Yes Female 3.1 4 6 Yes Obs No Alive
36 64342 24 Multi M Yes LN - No Male 3.4 5 6 No BA No Alive
37 68466 25 Multi M No Outlet FD Yes Female 3.25 7 8 No No No Alive
38 62240 18 Primi M Yes LN - No Male 2.8 7 8 No MAS No Alive
39 63782 19 Primi T No LSCS FD Yes Male 3.5 7 8 No MAS No Alive
40 63936 30 Primi M Yes LN - No Female 3.2 7 8 No No No Alive
41 64030 25 Primi T No Outlet FD Yes Male 2.3 4 5 Yes MAS No Expired
42 69803 23 Primi M No LN - No Male 3 5 7 Yes No No Alive
43 63990 26 Multi T No LSCS FD Yes Female 3.25 5 6 Yes MAS No Alive
44 69862 21 Primi T Yes Outlet FD Yes Female 3.4 5 6 Yes Obs No Alive
45 64900 21 Primi M No LN - No Male 2.5 7 8 No No No Yes
46 62211 26 Primi M No LN - No Male 3 7 8 No No No Alive
47 63649 25 Primi M No LN - No Male 2.5 6 7 Yes MAS No Alive
48 64055 24 Primi T Yes LN - No Female 2.7 6 7 No BA No Alive
49 70768 23 Primi M Yes LSCS FD Yes Female 2.5 4 5 Yes MAS,  HIE No Expired
50 64230 27 Multi M No LN - No Male 3.5 5 7 Yes MAS No Alive
51 71315 21 Primi T No LSCS FD Yes Female 2.6 7 8 No MAS No Alive
52 71837 29 Primi M No Outlet FD Yes Male 2.3 6 8 Yes Obs No Alive
53 71607 29 Primi T No LSCS FD Yes Female 3.5 6 8 Yes No No Alive
54 71529 39 Multi M No LN - No Male 2.6 7 8 No No No Alive
55 70844 21 Primi M No LSCS FD Yes Male 3.3 7 8 No No No Alive
56 72339 19 Primi M No LN - No Female 3 6 8 Yes MAS No Alive
57 72415 29 Primi T No LSCS FD Yes Male 2.6 7 8 No No No Alive
58 72671 24 Multi M Yes LN - No Male 3 5 7 Yes Obs No Alive
59 72991 19 Multi T No LN - No Male 2.5 7 8 No No No Alive
60 76065 20 Multi M No LN - No Male 3.1 6 8 Yes Obs No Alive
61 72818 18 Multi M No LN - No Female 2.2 7 8 No No No Alive
62 64219 20 Primi T Yes LN - No Female 2.75 7 8 No No Yes Alive
63 80841 27 Primi M No LN - No Female 3.4 7 8 No No No Alive
64 78395 22 Multi M Yes LN - No Female 2.75 7 8 No No No Alive
65 76251 25 Primi T No LSCS CPD No Male 2.75 6 8 Yes No No Alive
66 73852 18 Primi M No LN - No Male 2.9 4 5 Yes HIEII , MAS No Expired
67 76241 20 Multi M Yes LN - No Male 3.2 7 8 No No No Alive
68 75867 34 Multi M No LSCS FD Yes Male 2.8 7 8 No No No Alive
69 73864 24 Primi T No LSCS FD Yes Male 2.7 6 7 Yes Obs No Alive
70 73809 25 Primi M No LN - No Female 2.5 7 8 No No No Alive
71 76874 23 Multi M Yes LN - No Male 2.2 6 8 Yes MAS No Alive
72 74025 22 Multi M No LN - No Female 3.2 7 8 No No No Alive
73 76250 21 Primi T No LN - Yes Female 3 5 6 Yes MAS No Alive
74 77572 25 Multi T No LSCS FD Yes Male 3.7 7 8 No No No Alive
75 78350 21 Primi M Yes LN - Yes Female 2.7 7 8 No No Yes Alive
76 73933 27 Primi M Yes Outlet - No Female 3 7 8 No No No Alive
77 74063 23 Multi T No LN - No Male 3.3 6 8 No No No Alive
78 74207 24 Primi T No LSCS FD Yes Female 3 7 8 Yes MAS No Alive
79 74141 21 Multi T Yes LN - No Male 2.5 7 8 No No No Alive
80 80118 24 Multi M No Outlet FD Yes Male 2.7 5 6 Yes MAS, HIE No Expired
81 80448 22 Multi T No LN - No Male 3.2 6 8 Yes No No Alive
82 80806 25 Primi T No Outlet FD Yes Female 3 4 5 No HIE No Alive
83 74432 26 Multi M No LN - No Female 3.2 7 8 No No No Alive
84 81591 34 Multi M No LN - No Male 2.5 3 4 Yes MAS, HIE No Expired
85 83344 21 Primi M No LN - No Female 3.5 7 8 No No No Alive
86 83532 25 Primi M No LN - No Male 2.8 7 8 No No No Alive
87 74514 25 Primi T Yes Outlet - No Female 3.1 4 6 Yes MAS, HIE No Expired
88 82670 24 Multi T No LN - No Male 2.5 5 6 No No No Alive
89 83328 22 Multi M No LN - No Male 3.2 7 8 No No No Alive
90 80831 27 Primi T No LSCS FD Yes Female 3 7 8 Yes No No Alive
91 80817 25 Primi M No LN - No Female 3.5 7 8 No No No Alive
92 70172 25 Multi M No LN - No Male 3.1 7 8 No No No Alive
93 72381 20 Primi T No LSCS FD Yes Female 2.5 4 6 Yes MAS, HIE No Expired
94 54965 24 Primi M No LN - No Male 3.4 7 8 No No No Alive
95 54995 28 Multi T No LN - No Female 3.1 7 8 No No No Alive
96 60621 20 Multi T No LN - No Male 2.4 7 8 No No No Alive
97 74211 24 Multi M No LN - No Male 3.25 7 8 No No No Alive
98 74145 28 Multi T No LN - No Female 3 7 8 No No No Alive
99 808115 26 Multi M No LN - No Female 2.7 6 7 Yes Ob No Alive
100 84432 25 Multi T No LN - No Female 2.75 7 8 No No No Alive
